• New application for manure treatment unveiled that meets the standards of the EU
• Process is highly versatile, capable of application on all types of animal farms
• Licensing agreements with various industries create applications of the water treatment technology that benefit both business and environment

Spain’s Depuporc, a company specifically focused on wastewater treatment on hog farms, unveiled an integrated manure-treatment system using OriginClear Inc. (OTC: OCLN) technology. The demonstration system showcases the processing of 30 metric tons per day with client-validation reduction of contaminants for pig farmers. OLCN technology poses major disruptive potential for the animal wastewater treatment sector. The full Depuporc system presentation video can be viewed at http://ibn.fm/suhpi.

In a television interview with Donald Baillargeon (http://ibn.fm/cUhH6), OriginClear CEO Riggs Eckelberry shared how Depuporc is benefiting from the technology, noting that the Depuporc system is a big step forward in processing manure wastewater to meet the requirements of the European Union. The EU requirements are stringent, and as a result are limiting core pork producers from expanding. The application of OriginClear’s technology is not just limited to one type of animal farm – it has tremendous versatility, Eckelberry observed. While Depuporc is focused on hog manure, the process can be readily applied and configured to cattle, poultry and other types of animal farms.

“[Depuporc] knows the ability to reduce ammonia is mission critical, and we are now exploiting this technology to the rest of our network,” Eckleberry stated in the interview. He later explained that OriginClear has established a preferred relationship with Depuporc that will allow OriginClear to take full advantage of the system in Europe while also relicensing, which enables the company to market the system in other parts of the world.

Eduardo Chopo Fraguas, co-owner of Depuporc, is excited about the possibilities of the technology. In 2018, Depuporc demonstrated the pilot system to Spanish farmers to show the efficiency of the process. “The technology of OriginClear has simplified our system,” stated Fraguas. “Simplifying the technology simplifies the cost and therefore makes it much simpler to deliver to market.” What is being developed applies to all animal farming, where an overabundance of manure of any type can hinder expansion. The technology has the potential to set a new industry standard.

OriginClear’s business model is to create licensing agreements with various industries that create applications of the water-treatment technology. OriginClear is seeking to restore water to its natural condition through these products and applications.

“The idea is that licensees come up with these complete products for their world,” stated Eckleberry. “We can’t know every single world, right? They come up with applications for their world, and those are cross marketed elsewhere in the network, and then other licensees come up with theirs and that creates sort of a synergy across a growing network. We think that is the only way you can possibly take advantage of our core technology which has to have this productization, you might say, for each industry.”

OriginClear is a leading provider of water-treatment solutions that provides businesses with the ability to treat their own water. On-premise systems enable high purification and recycling levels that increase property values and become productive assets for businesses. Industries that OriginClear is currently focused on include commercial, real estate, hospitality, food and beverage, business parks, industrial, oil, gas, energy, agriculture, pharmaceutical and manufacturing. The company plans to ramp up marketing and begin to make a significant impact on the environment as well as the animal-farming industry.

For more information, visit the company’s website at www.OriginClear.com

NOTE TO INVESTORS: The latest news and updates relating to OCLN are available in the company’s newsroom at http://ibn.fm/OCLN

• SGLB recognized as creator of 3D printing industry’s most innovative quality-assurance software.
• The company has secured key relationships with major industry players Materialise, NV;Siemens AG; and Airbus
• Global 3D-printing metal market expected to grow at CAGR of 31.8%, exceeding $3 billion by 2025

Sigma Labs Inc. (NASDAQ: SGLB) is a leading developer of quality control software for the commercial 3D-printing industry. The company’s PrintRite3D® software, a proprietary real-time, computer-aided inspection (CAI) technology, represents a seismic shift in the quality-assurance process in the manufacture of 3D-printed metal components, and the entire sector is poised for extraordinary growth.

3D metal printing technology, also known as additive manufacturing, allows producers to transform a 3D-modeled digital object into a three-dimensional physical object by adding material layer by 10 to 30-micron layer, rather than subtracting it as in the traditional manufacturing process.

Sigma Labs has been recognized as the creator of the industry’s most innovative quality-assurance software which is poised to help unleash commercial 3D metal printing by enabling nondestructive, in-process quality control, Sigma Labs has already engaged with renowned industry players such as Materialise NV, Siemens AG and Airbus.

Materialise, one of the most innovative developers of additive manufacturing software and printing solutions, has integrated Sigma Labs’ PrintRite3D technology with its Materialise MCP controller and jointly demonstrated the latest version of the software platform at Formnext, the premier, global, 3D-printing exhibition and conference held in Frankfurt earlier this year.

Siemens AG assisted Sigma Labs in advancing the early version of PrintRite3D INSPECT 2.0 towards version 5.0. One of the largest global oil-field services companies has entered the final stage of the PrintRite3D rapid-test and evaluation program, the last step before commercial orders. Sigma Labs also has a test and evaluation program with European aerospace giant, Airbus.

• Now embraced by a myriad of global industrial producers, 3D metal printing is set to beneficially disrupt the $12 trillion global manufacturing industry (http://ibn.fm/CgZP0). The global 3D-printing metal market is expected to grow at an eye-popping CAGR of 31.8% and exceed $3 billion by 2025 (http://ibn.fm/yXmdA). Still, the nascent industry’s growth is hindered by a very costly and burdensome quality-control process, which impedes production at scale.

1. Edwards said, “Inspection does not improve the quality, nor guarantee quality. Inspection is too late. The quality, good or bad, is already in the product. As Harold F. Dodge said, “You cannot inspect quality into a product.”

Due to the variability of the 3D metal printing process, consistent quality and inspection of produced parts is not reliably achievable without substantial postproduction inspection using expensive CT scans and other means, which result in high part rejection, lost time, lost profits and inability to economically scale up production with reduced confidence. “In process inspection develops a pathway to a decision ecosystem that enables confidence in part quality” Beckett. When these operational and production challenges are resolved, the whole industry will grow even faster than projected.

Sigma Labs’ PrintRite3D is the only solution that enables real-time, in-process, quality-assurance tools to observe manufacturing complexities while detecting irregularities and to intervene and avert loss of products by alerting operators in-process and enabling them mitigate the emerging problem(s). Sigma Labs is currently in the execution and delivery phase of commercial development. Millions of dollars have been invested in R&D, refining the latest PrintRite3D 5.0, protecting the IP and working with 19 beta customers, some of which are the biggest names in the industry.

Recognizing the vast potential of the emerging 3D printing industry to revolutionize the traditional manufacturing process, investors have long been investing capital into 3D-printing companies as different sectors of et industry have grown and many industrial applications are flourishing. The overall industry has already created three companies valued in excess of $1 billion. 3D-printing unicorn Carbon is the highest valued of these venture-backed startups, raising $680 million, at a valuation of $2.4 billion, from prominent investors that include Sequoia Capital, GV, Madrone Capital Partners and Baillie Gifford.

Sigma Labs’ people and flagship software PrintRite3D are recognized game changers in the technologies poised to transform the greater-than-$1-billion, yet still nascent, 3D metal printing industry.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

• MCTC Holdings Inc. is engaged in developing infusion technologies, including nanoparticles, for making hemp extracts more bioavailable to users through the bloodstream
• The company has a particular goal of promoting beverage infusion superior to anything existing in the industry as a potential replacement for alcohol and alcohol’s negative health effects
• MCTC has filed its fifth patent under its Hemp You Can Feel brand after lab results exceeded the company’s expectations for demonstrating cannabis particle infusion on a minuscule, undetectable basis

Cannabinoid science innovator MCTC Holdings Inc. (OTC: MCTC), a Delaware-registered, fully reporting company, has applied for what would be its fifth patent even as laboratory results indicate its revolutionary Hemp You Can Feel™ brand technology has exceeded expectations when it comes to infusing beverages, powders and liquid concentrates to such a degree that all hemp extracts and major cannabinoids are undetectable.

“We believe the uses for this advanced infusion technology are many, especially as a replacement for alcohol in various beverages,” MCTC Holdings CEO Arman Tabatabaei stated in a news release (http://ibn.fm/clSAc).

The Hemp You Can Feel innovation was introduced last month as a beverage industry solution for delivering relaxation to consumers without the negative health effects associated with alcohol consumption. The brand’s technology is based on an all-natural manufacturing process that doesn’t depend on any chemical surfactants, stabilizers or additives.

MCTC Holdings has been experimenting with cannabis-based polymeric solid nanoparticles and nanofibers, and while the company’s latest step forward involves non-nanoparticle technologies, they do nonetheless demonstrate chemical property levels many magnitudes lower than those typically seen in the marketplace.

The food and medical industries have long used nanoparticles to turn extremely small substances into rapid delivery mechanisms that can bypass the digestive system and go straight for the bloodstream, and the science is ripe with potential for cannabis applications. MCTC’s technology makes it possible to use very small amounts of extracts to achieve similar or superior results compared to other infusion methods.

MCTC plans to use the technology in products it expects to launch during the coming months as well as using it for the basis of a licensing strategy that will allow other companies to build branding from it on a “white label” manufacturing base at MCTC’s licensed Los Angeles facility.

The company announced December 12 it was filing for a new patent subsequent to the positive test results.

“We have produced some spectacular results and test data on this new technology and we are in discussions with several companies that are planning product introductions based on Hemp You Can Feel technology,” Tabatabaei stated (http://ibn.fm/bJ5AY). “This marks our 5th patent with several more expected over the short term.”

Tabatabaei stated the next step for the company will be to create microparticle and nanoparticle forms of Hemp You Can Feel, and that development work has already begun toward that end. The company is also in the process of developing nanoparticle creation protocols for the cannabinol (CBN) extract and tetrahydrocannabivarin (THC-V) compound.

CBN is found only in small amounts and mostly results from oxidation of the other cannabinoids in cannabis, making it difficult to obtain and expensive as a result. An effective, minuscule-amount-tapping technology could make its use more cost-effective. THC-V is similar to tetrahyrdrocannabinol in molecular structure but has different outcomes, such as appetite suppression and bone-growth promotion (http://ibn.fm/2UUlu).

“We think these new microparticle and nanoparticle technologies could prove very useful for advanced food and beverage infusion,” Tabatabaei stated. “We believe this additional area of research is especially topical considering the recent warnings put forth by the U.S. Food and Drug Administration concerning the use of CBD in foods and beverages.”

On November 25, the FDA announced a warning to more than a dozen companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act, including marketing CBD products to treat diseases or for other therapeutic uses for humans or for animals.

Under the FD&C Act, a product qualifies as a drug if it claims to treat a disease or to have some other therapeutic or medical use, and is intended to affect the structure or function of the human or animal body other than for simple alimentary purposes. No CBD-based “drug” has been approved on a federal basis except for one company’s prescription to treat rare, severe forms of epilepsy in humans, so other CBD products marketed on an interstate basis may be found in violation, according to the FDA’s news release (http://ibn.fm/U8Ory).

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC

• OriginClear key partner in water-treatment system that transforms manure into zero-waste output of fertilizer, clean irrigation water
• Meeting government regulations for ammonia levels major hurdle for pork producers in Spain
• “Game changer” system already driving deal flow for OriginClear

OriginClear Inc. (OTC: OCLN), a leading provider of water-treatment solutions, and Depuporc S.L., the company’s Spain-based licensee (http://ibn.fm/VFPoj), have partnered to build a comprehensive water-treatment system that continuously transforms pig manure into a zero-waste output of fertilizer and clean irrigation water (http://ibn.fm/R8u8G). The system could be transformative in the country, which is the world’s fourth-highest pork producer, positioning OCLN for significant market penetration.

OriginClear CEO Riggs Eckelberry recently returned from a trip to Spain. There, he participated in a demonstration of the system, which allows companies to dramatically increase production while still complying with strict European Union environmental limits.

“Until recently, swine farm operators in Spain have irrigated their fields with manure effluent,” Depuporc co-owner Eduardo Chopo stated in a news release. “Most operators in the region are planning large increases in hog farming, but their lands are already saturated with ammonia. Strict EU limits make ammonia reduction absolutely essential before increases in swine production can occur.

“The logical solution for these operators is to treat the manure for fertilizer and water reuse,” he continued. “This is where our patented system, which incorporates OriginClear’s technology as a third and final step, has been shown to reduce pollutants and also generate valuable fertilizer and irrigation-grade water, solving a major barrier to expansion for European hog farmers.”

The Depuporc demonstration system processes 30 metric tons per day, with the demonstration system reducing COD (chemical oxygen demand) from 83,000 to 300 mg/liter and ammonia from 11,000 to 230 mg/liter.

“As manure decomposes, it creates ammonia, which makes the soil more acidic, harming plant and animal life, and indirectly, human health,” explained Eckelberry (http://ibn.fm/nWrrI). “So Europe — and the rest of the developed world — closely regulates ammonia emissions. Most of Europe has been doing a good job of reducing ammonia, but Spain’s emissions have gone up, not down.

“Now, the country’s pork producers are up against a Spanish law that limits nitrogen production to 210 kilos per hectare per year,” he continued. “And what does the Depuporc system achieve with our technology? How about 16 kilos? That’s a game changer, and it’s already driving deal flow for us in the United States.”

In addition to participating in the system presentation, Eckelberry and Bill Charneski, president of the OriginClear Group, toured the facility and other farms in the region (http://ibn.fm/n7yLq).

“With its system protected by Spanish patent No. 2011311192, Depuporc has hit a home run,” Eckelberry said. “They have integrated our technology to effectively reduce solids and ammonia in a working field manure treatment system.”

OriginClear is a leading provider of water treatment solutions. The company offers breakthrough water-treatment and conveyance products that effectively improve the quality of water by returning it to its original and clear condition. OCLN’s stated mission is to empower this global movement with products that enable water independence and help make clean water available for all. The company provides modular water-purification systems, storage systems, pump stations, wastewater systems and control systems.

For more information, visit the company’s website at www.OriginClear.com

NOTE TO INVESTORS: The latest news and updates relating to OCLN are available in the company’s newsroom at http://ibn.fm/OCLN

• MCTC Holdings Inc. is a company dedicated to research and development of innovative infusion technologies in the fast-growing area of cannabinoids sciences
• The company recently announced that it is expanding on development infusion technologies to include lesser known cannabinoids such as cannabinol (CBN) and THC-V, which have possible applications in product that promote sleep and control appetite
• MCTC has thus far filed five patents and expects to file at least several additional over the coming months
• The company’s aim is to make the current generation of hemp extract and cannabinoid technologies obsolete

Cannabis infusion technology developer MCTC Holdings Inc. (OTC: MCTC), a Delaware-registered, fully reporting company, is expanding its research beyond the four patents the company has developed with the aim of establishing novel applications of polymeric nanoparticles of cannabinol (CBN) and cannabinoid glycosides.

Since MCTC Holdings reorganized itself in June, the company has focused its corporate efforts on the fast-growing cannabis industry, specifically the development of products that build on proprietary research into exotic cannabinoid isolation, bioenhancement of cannabinoids and polymeric solid nanoparticles and nanofibers that can be added into consumer products and applied through the skin.

“The polymer-based nanoparticles being developed by MCTC significantly differ from the simple oil-in-water nanoemulsions being marketed as interim solutions for the food and beverage industry,” the company stated in a press release (http://ibn.fm/4zyUy). “The polymer-based particles the Company is developing will allow for significant loading of active ingredients and unparalleled flexibility in creating custom cannabinoid combinations with unique performance characteristics.”

Nanotechnology involves the study of extremely small things, and it is a science that has been used in the food and medicine industries for some time to help humans more effectively utilize the beneficial compounds of food and medicine products. Nanoparticles are directly absorbed into the bloodstream, which allows for a quicker and more effective bio-delivery of their properties than is accomplished through digested substances (http://ibn.fm/OOIdf).

MCTC has been developing nanotechnology’s potential within the cannabis industry, focusing on the potential of microscopic properties in cannabidiol (CBD) by patenting an innovative edible dissolvable film, a water-soluble form of vitamin E, a unique 3D-printed cannabinoid delivery system for beverages, and a broad-property means of dispersing nanoparticles and nanofibers. A fifth patent application is in process.

The company now aims to use its CBD R&D experience in the development of uses for some of the minor cannabinoids, with CBN as the first target. CBN is found only in small amounts and mostly results from oxidation of the other cannabinoids in cannabis, making it difficult to obtain and expensive as a result. But MCTC believes CBN nanoparticles have the potential to deliver the cannabinoid’s beneficial properties in minuscule amounts as an alternative to the volumes used currently for formulation.

MCTC is also researching the potential of cannabinoid glycoside nanoparticles. Glycosides are molecular compounds that involve the binding of a sugar to another compound. Many plants store chemicals in the form of inactive glycosides, and glycosides play numerous important roles in living organisms (http://ibn.fm/5SjLG).

MCTC states that one of its purposes in developing the nanoparticles is for potential use in managing controlled and sustained drug release requirements. For example, several studies indicate CBN may counteract some of the negative effects of other cannabinoids and the creation of particles containing both CBN and other cannabinoids, especially psychoactive cannabinoids, could lead to new opportunities.

As part of the company’s renewed focus on the cannabis industry, MCTC is anticipating a name change to Cannabis Global Inc. in the near future.

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC

• Trxade offers drug producers and distributors a transparent trading platform with significant discounts for pharmacies
• Platform currently has 11,500 independent pharmacies as registered users, reaching an estimated 12 to 15 million patients
• The company plans to add other healthcare providers to its platform in a future phase
• During Q3 2019 the company recorded a significant 173 percent increase in revenues
• Subsidiary Bonum Health established a partnership with Benzer Pharmacy to launch health hubs in areas where residents don’t typically afford primary or collaborative care

Business-to-business pharmacy services supplier Trxade Group Inc. (OTCQB: TRXD) has remained consistently profitable over the last couple of years, reporting seven consecutive quarters of revenue growth, as it continues to expand its services and reach more patients nationwide, CEO Suren Ajjarapu said in a recent interview with NetworkNewsWire (http://ibn.fm/DGhC8).

Offering an online purchasing platform for transactions between independent pharmacies and drug distributors, along with a mail order pharmacy, a Telemedicine platform and drug delivery service, Trxade has registered roughly 123 percent quarter-on-quarter revenue growth in 2019 compared to 2018, Ajjarapu noted. The company recently announced record revenues that marked a 173 percent increase in year-over-year third quarter sales, driven largely by last year’s acquisition of Community Specialty Pharmacy, LLC, a Florida-based business-to-consumer operation that includes online access certified independently with 15 state licenses (http://ibn.fm/bk3j3).

Trxade’s proprietary web-based e-commerce platform enables trade among pharmaceutical, accessory, and service buyers and sellers. Currently, the platform has about 11,500 pharmacies as registered users, through which it reaches between 12 million and 15 million patients. The company aims to reach most, if not all, of the estimated 24,000 independent pharmacies currently operating in the U.S., with combined pharmaceutical purchases of $93 billion per year. The company is adding over 100 pharmacies to its platform per month and has plans to soon provide access to other healthcare providers, such as hospitals, veterinary clinics and long-term care facilities.

The trading platform developed by Trxade offers its users a series of measurable benefits, including significant discounts that contribute to a 7-10 percent decrease in the annual purchase expenses for pharmacies; no registration and transaction fees for pharmacies; a simple and intuitive interface that helps pharmacies compare prices and select the best offer with guaranteed security for purchases and payments.

During the interview, Arjjapu also discussed Trxade’s recent acquisition of Bonum Health, which offers similar services with large-chain pharmacies such as CSV, Walgreens and Walmart, that allow patients to both talk to a doctor and pick up medication at the same location. Some locations offer a wide range of other services such as dental, vision and hearing services. Trxade is also ready to make available a growing number of services through the Bonum app. “In the future, patient care is moving from the doctors to the pharmacy side of it,” Ajjarapu said in the interview. “We are taking that challenge ahead of the time now, so that we are prepared for that when it really happens.”

To further expand operations, Trxade recently sealed a partnership between Bonum Health and Florida-based Benzer Pharmacy (http://ibn.fm/wyODr). The goal of this partnership is to create a network of “Bonum Health Hub” units in small towns and rural areas where residents do not typically afford primary or collaborative healthcare. For now, Bonum Health and Benzer Pharmacy plan to open 100 units by the end of 2020. The companies plan to attract various independent pharmacies in this partnership established under the slogan “People First.”

All recent acquisitions and partnerships are part of Trxade’s strategy to increase shareholder value and advance its business model. The company is currently working to uplist its common stock on the Nasdaq Capital Market. “We’ve been under the radar for a long time. We’re trying to create visibility along the investor base by doing the right thing so we can get on to that uplisting,” Ajjrapu concluded.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• Several parties have indicated interest in potential acquisition of POAI’s Skyline Medical division
• The division has seen recent success with growing sales of its patented, FDA-approved STREAMWAY System
• POAI also regained compliance with Nasdaq’s minimum bid price requirement

Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has revealed that several parties have indicated interest in the potential acquisition of Skyline Medical, the division of the company that produces and sells the STREAMWAY System (http://ibn.fm/fjuZr). The patented, FDA-approved STREAMWAY System is the first truly continuous, direct-to-drain fluid disposal system designed specifically for medical applications.

In the past several months, Skyline Medical has seen marked success with the system, including the completion of the sale of 10 systems to the foremost teaching and research hospital in upstate New York (http://ibn.fm/gxRIf). The sale surpasses the company’s largest single-hospital sale to date and is only one indication of Skyline Medical’s focus on making significant inroads in the U.S. market and expanding sales globally.

“I am exceptionally pleased with the rapid growth and development of our Helomics and Tumor Genesis divisions, as well as the multiple indications of interest for our Skyline Medical division,” POAI CEO Dr. Carl Schwartz stated in a news release. “If this results in the sale of Skyline Medical, it would not only provide additional working capital, it would also allow Predictive Oncology to focus on the further development and commercialization of our two divisions focused on precision medicine.”

Previously POAI had announced that it will be focusing primarily on the mission of applying artificial intelligence to precision medicine and drug discovery, sending a message to the market that its Skyline Medical division may be available. Updates on the future of the division may come in early 2020 as POAI evaluates options that will produce the greatest value for its stockholders. Although the company has received indications of interest, company officials note that there is no assurance that acceptable offers will be received or that a definitive agreement or sale will be completed.

In other POAI news, the company announced that it has regained compliance with Nasdaq’s minimum bid price requirement (http://ibn.fm/au9Vz). The company recently received a notification letter indicating the change in status. In November 2018, POAI was notified that the company did not meet the minimum price bid requirement. In order to meet the requirement, the letter stipulated that the closing bid price for POAI needed to be at least $1.00 for 10 consecutive business days. That occurred from October 29, 2019, to November 11, 2019, resulting in POAI regaining compliance.

Predictive Oncology, which began as a joint venture between Skyline Medical and Helomics, is ideally positioned to harness the power of artificial intelligence and work alongside the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for cancer patients.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• No Borders Inc. is a multi-faceted technology innovator and marketing company focused on infiltrating and disrupting verticals that are behind the curve of technological adoption
• No Borders recently announced its first publicly accessible blockchain product, CBD LabChain, as a means of providing CBD product purity openness to consumers and revenue to the company as it helps Hemp brands to prove their product purity and efficacy
• The company is built on a lean, remote-work operating system that encourages creativity and minimizes costs, thereby maximizing shareholder value
• The company’s most recent quarterly report showed quarter-over-quarter revenue growth of 25.57 percent as well as an increasing gross profit margin

The reported wellness benefits of non-euphoric cannabis products such as cannabidiol, better known by the trade marketing initials CBD, are making products such as CBD a household medicine cabinet staple in an increasing number of homes all across North America (http://ibn.fm/lb44J), not only among young adults but also among potentially more conservative members of the over-50 senior market – a recent Gallup poll showed one in five respondents under 29 years old reported using CBD, and nearly one in five older than 50 similarly reported using it (http://ibn.fm/C2jSe).

At the same time, consumer advocates are raising alarms about the reliability of CBD product claims – a San Diego TV station recently reported on a local lab’s findings that numerous CBD products lacked any CBD, misrepresented the amount of CBD, or were tainted by potentially harmful substances (http://ibn.fm/e1evp). Forbes (http://ibn.fm/WvLia) also noted recently that hemp-derived CBD is “poised to overtake olive oil in the category of most counterfeited plant extract on the planet,” because of an undeveloped federal regulatory process in the United States. The U.S. military complex has banned CBD use among the various services because of uncertainties about potential euphoric drug taint in marketed products (http://ibn.fm/k9uN0).

Innovative technology solutions provider No Borders Inc. (OTC: NBDR) is focusing its expertise in Distrubuted Ledger Technology also known as “blockchain” on improving the reliability of CBD products. The company announced its first publicly accessible blockchain product, CBD LabChain, in November as part of a platform-building venture that will grant consumers immutable, secure and open access to laboratory test results for CBD products (http://ibn.fm/I8Q9j).

The company’s subsidiary No Borders Labs uses cutting-edge technology to provide clients and other No Borders portfolio companies with world-class Internet-based tools, including data analytics, technological innovation and tech support. Through CBD LabChain, No Borders is looking to build a revenue stream based on a per-test fee Platform As A Service (PAAS) model that provides a clear and highly in demand trust layer to the consumer while helping retailers in the lucrative CBD marketplace to showcase the efficacy of their products.

As the military’s ban on CBD shows, a significant concern among potential product users is the potential for cannabis-derived CBD substances to also contain significant levels of cannabis plants’ tetrahydrocannabinol (THC) chemical extract. While CBD contains some minimal psychoactive properties regarded as desirable for pain relief, THC is a stronger euphoria-inducing extract that provides the basis of marijuana drug products, and the fact that both extracts are derived from cannabis leads to the possibility both might exist in a cannabis product that has not been adequately vetted.

Hemp Magazine recently highlighted the economics involved in product testing, citing both a CBD consumer jailed on a felony charge because of a traffic stop that led to the discovery her CBD bottle had too much THC content under state law, as well as a hemp farm that spent $35,000 to $40,000 per year on lab testing before deciding to create its own testing facility (http://ibn.fm/DuheI).

No Borders operates on a lean, remote-work corporate model (http://ibn.fm/u4uta) that allows it to not merely foster creativity but also to manage costs in verticals whose existing market participants are behind the curve of technological adoption, which generates large profit opportunities for the company as well. The company’s most recent quarterly report showed quarter-over-quarter revenue growth of 25.57 percent and a gross profit margin that increased from 35.03 percent to 42.47 percent.

“Clearly, this filing shows that the Company is deploying capital to its brands and businesses at almost a 100% rate,” No Borders COO Cynthia Tanabe stated in a news release (http://ibn.fm/6ssC6). “This is a strong indicator of how much faster and farther the NBDR brands can go with the addition of capital through the Company’s recent SEC filings.”

No Borders received “qualification” approval from the Securities and Exchange Commission for a Reg A offering to raise up to $3 million in investments in November, and has subsequently received approval from the states of New York and Colorado to seek investors there (http://ibn.fm/IBWFa). The company has also applied for Reg A qualification in Florida and anticipates pursuing similar efforts in several additional states, “to raise capital while mitigating and minimizing negative dilutive impacts to the business and its shareholders.”

For more information, visit the company’s website at www.NBDR.co

NOTE TO INVESTORS: The latest news and updates relating to NBDR are available in the company’s newsroom at http://ibn.fm/NBDR

• POAI sees Q3 2019 revenue total $522,696 from $329,930 in Q3 2018
• Company reports records sales of proprietary systems, supplies
• Significant business highlights indicate continued momentum as Predictive Oncology looks to bright future

Predictive Oncology Inc. (NASDAQ: POAI), an artificial intelligence (AI) and data-driven functional precision medicine company, released its financial results for Q3 2019, and the numbers are impressive, including quarter revenues increasing 58% year over year (http://ibn.fm/TmZoV). The company also provided a business update outlining significant highlights reached during the quarter.

POAI reported that revenue for the quarter ended September 30, 2019, totaled $522,696, compared with $329,930 for the same period of 2018. Those numbers included revenue from record sales of the company’s STREAMWAY systems and disposable supplies. Predictive Oncology reported the sales of 19 STREAMWAY systems, a significant increase when compared to 10 sales of the system during the comparable period in 2018.

Cost of sales for Q3 2019 was $208,096 compared to $83,006 in the same period of 2018. Gross profit margin declined to 60% percent versus 75% in the third quarters of 2019 and 2018 respectively. Operating expenses for the quarter ended September 30, 2019, totaled $707,414 down from $723,939 for the third quarter of 2018. General and administrative expenses were $2,616,991 for Q3 2019, compared to $762,603 during Q3 2018. Sales and marketing expenses declined significantly, totaling $434,955 in Q3 2019 compared to $621,465 for the previous year.

In addition to the impressive numbers, POAI noted several Q3 2019 business highlights, including the following:

• Initial models in progress with Interpace Diagnostics for Thyroid
• Helomics has initiated pilot sequencing of 48 samples
• ChemImage working on additional validation utilizing POAI platform and AI (D-CHIP) in prostate cancer
• Specicare ‘Pioneer’ Precision Medicine trial in progress
• Predictive Oncology continues to execute on Cancer Quest 2020
• POAI subsidiary TumorGenesis has initiated the building of media kits to allow the growth of ovarian cancer cells in its labs.
• Clinically validated, patient-derived (PDx) tumor profiling platform to generate drug response profiles and multi-omic data
• Data on drug response profiles of more than 150,000 tumors across 137 cancer types using the PDx platform in more than 10 years of clinical testing.

“I am very pleased with the growth and development of our unique assets, Helomics and Tumor Genesis, and the increase in international interest in our Skyline products,” POAI CEO Dr. Carl Schwartz stated in a news release. “The future looks very bright.”

Predictive Oncology is committed to the mission of improving the standard of care for cancer patients through innovative, data-driven products and services. The company provides predictive models of tumor drug response to improve clinical outcomes for patients. POAI is at the vanguard of the latest scientific endeavors in cancer research to better understand the complexities of individual cancers and tailor individualized therapeutic protocols.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• POAI subsidiary sequencing ovarian cancers as part of CancerQuest 2020 project, building largest ovarian multi-omic database in the world
• Company’s work designed to speed development of new drugs, provide therapeutic choices
• Helomics recently signed collaborative agreement with UPMC-Magee to establish data- and artificial-intelligence-driven approach to treating ovarian cancer

The power of artificial intelligence (AI) to assist in the detection of ovarian cancer much earlier than previously possible is being recognized worldwide. A company in the United Kingdom is touting the ability of AI to eliminate late detection of ovarian cancer, thanks to advancements in health-care technology (http://ibn.fm/AOmHt). The contribution AI is making in the detection of ovarian cancer has been a longtime, consistent focus for Predictive Oncology Inc. (NASDAQ: POAI) as well.

Predictive Oncology recently began sequencing ovarian cancers as part of its CancerQuest 2020 project and is building the largest ovarian multi-omic database in the world, designed to speed the development of new drugs and provide better therapeutic choices. Predictive Oncology’s subsidiary, Helomics, is vital to the CancerQuest2020 work POAI is doing in the ovarian cancer space.

Helomics currently has approximately 150,000 cases on its molecular information platform, 38,000 of which are specific to ovarian cancer. This invaluable scientific asset positions POAI as a leader in providing the critical molecular information needed for more effective patient treatments and new drug discovery.

As part of its CancerQuest 2020 project, Predictive Oncology, through Helomics, recently signed a collaborative agreement with UPMC-Magee to establish a data- and artificial-intelligence-driven approach to treating ovarian cancer. Based on the agreement, the partnership is designed to validate the significant value of using AI-powered decision-making for identifying specific treatments on specific genotypes to predict clinical outcomes for ovarian cancer patients.

Helomics has also begun sequencing retrospective ovarian cancer cases from the UPMC-Magee collaboration (http://ibn.fm/I4Lnb). As part of the sequencing process, Helomics is analyzing the mutations in the tumor (genome) and the expression of genes (transcriptome) in order to build a comprehensive multi-omic picture of the tumor. That information can then be brought together with Helomics’ data set of drug-response profiles to build an AI-driven predictive model of ovarian cancer.

“We believe the combination of the rich multi-omic profile of the tumor and clinical outcome data will allow us to build an AI-driven model of ovarian cancer capable of predicting the tumor drug response and patient outcome,” Helomics CTO Dr. Mark Collins stated in a news release.

In addition to its ovarian-cancer data, Helomics has another 120,000 tumors with drug-response data across 137 cancer types that include lung, breast, pancreatic, colon and head and neck. Moving forward, the company intends to sequence all the tumors and build out predictive models in these additional disease categories. Once this work is complete, Helomics will have the largest pan-cancer, multi-omic database with drug responses in the market.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI